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Abstract
Background: Neuropsychiatric symptoms (NPS) are very common in patients with mild cognitive impairment (MCI)
and Alzheimer’s disease (AD) dementia and are associated with various disadvantageous clinical outcomes including a
negative impact on quality of life, caregiver burden, and accelerated disease progression. Despite growing evidence of
the efficacy of (non)pharmacological interventions to reduce these symptoms, NPS remain underrecognized and
undertreated in memory clinics. The BEhavioural symptoms in Alzheimer’s disease Towards early Identification and
Treatment (BEAT-IT) study is developed to (1) investigate the neurobiological etiology of NPS in AD and (2) study the
effectiveness of the Describe, Investigate, Create, Evaluate (DICE) approach to structure and standardize the current care
of NPS in AD. By means of the DICE method, we aim to improve the quality of life of AD patients with NPS and their
caregivers who visit the memory clinic. This paper describes the protocol for the intervention study that incorporates
the latter aim.
Methods: We aim to enroll a total of 150 community-dwelling patients with MCI or AD and their caregivers in two
waves. First, we will recruit a control group who will receive care as usual. Next, the second wave of participants will
undergo the DICE method. This approach consists of the following steps: (1) describe the context in which NPS occur, (2)
investigate the possible causes, (3) create and implement a treatment plan, and (4) evaluate whether these interventions
are effective. Primary outcomes are the quality of life of patients and their caregivers. Secondary outcomes include NPS
change, caregiver burden, caregivers’ confidence managing NPS, psychotropic medication use, the experiences
of patients and caregivers who underwent the DICE method, and the cost-effectiveness of the intervention.
Conclusions: This paper describes the protocol of an intervention study that is part of the BEAT-IT study and
aims to improve current recognition and treatment of NPS in AD by structuring and standardizing the detection
and treatment of NPS in AD using the DICE approach.
Trial registration: The trial was registered on the Netherlands Trial Registry (NTR7459); registered 6 September 2018.
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Introduction
Background and rationale
The majority of patients with Alzheimer’s disease (AD)
experience neuropsychiatric symptoms (NPS) during the
course of their disease [1, 2]. NPS include behaviors
such as apathy, agitation, and psychosis, and are already
highly prevalent in patients in the early stages of AD
including those with mild cognitive impairment (MCI)
[3]. NPS have a large impact on the quality of life (QoL)
of patients and their caregivers [4], leading to extensive
healthcare costs [5]. In addition, NPS are related to
accelerated progression of the disease and earlier
institutionalization [6, 7].
Although NPS are increasingly recognized as core
features of AD [2], NPS are currently underrecognized
during the diagnostic phase in memory clinics. This
notion arises from our local experience, but one that has
also been raised previously by several international
research groups [8–12]. While cognitive testing and
instrumental activities of daily living (IADL) question-
naires are typically administered during standard clinical
work-up, assessment of NPS (e.g., using the Neuropsy-
chiatric Inventory (NPI)) is often not [13]. The failure of
clinicians to prioritize the assessment of NPS leads to
undertreatment and a variety of associated suboptimal
outcomes [14, 15]. This is clearly a missed opportunity
since there is growing evidence for the efficacy of psy-
chosocial and pharmacological interventions to reduce
NPS and improve QoL in patients with AD [16–19].
NPS are often considered as medication targets in
cases where NPS are appropriately detected by clinicians
[11]. This leads to high rates of (off-label) psychotropic
medication prescriptions that are only modestly effective
in dementia [20]. In addition, this symptomatic treat-
ment does not do justice to the multiple contributors
causing NPS, including factors relating to the patient
(e.g., personality), caregiver (e.g., communication style),
and environment (e.g., safety) [11, 21, 22]. Therefore, a
patient-centered care (PCC) approach is preferred that
considers all these individual factors when managing
NPS [1, 17, 23].
After a comprehensive assessment of NPS, nonphar-
macological interventions are the first choice to treat
NPS in dementia as recommended by the national and
international guidelines on the diagnosis and treatment
of dementia [24–26]. Although several psychosocial
interventions have been developed and proven to be
effective (e.g., [27–29]), these programs have rarely been
implemented into standard care in memory clinics [10].
Previous studies have suggested various barriers to
implementing these guidelines, including a lack of
training and knowledge among clinicians regarding
the efficacy, dosing, and timing of nonpharmacological
interventions [22, 30]. Nonpharmacological strategies are
also considered to be more time-consuming compared to
psychotropic medication. Furthermore, there are only
limited evidence-based interventions suitable for patients
with early-stage dementia and their caregivers given the
focus of previous research on institutionalized patients
with severe dementia [31]. To overcome these barriers,
there is a need for a tool that translates the current guide-
lines into clinical practice and integrates a comprehensive
assessment into the standard work-up at memory clinics
in order to improve early recognition and tailored treat-
ment of NPS in AD.
Recently, a multidisciplinary expert panel proposed
such a tool that integrates current models and theories
on the causes of NPS to structure the assessment and
management of these symptoms following four steps:
Describe, Investigate, Create, Evaluate—i.e., the DICE
method [10]. This framework identifies NPS, examines
possible underlying causes, and consequently integrates
pharmacological and nonpharmacological interventions
to treat these symptoms following a PCC approach.
Similar approaches to the DICE method have been
developed to address NPS in dementia (e.g., “Grip on
Challenging Behaviour” [32], “4D Approach” [33], “Act
in Case of Depression” [34], “STA OP!”) [35]. However,
studies in community-dwelling patients are lacking, as
the majority of these methods have been carried out in
the nursing home setting. A recent pilot study showed
that the use of the DICE method reduced caregiver
distress in caregivers of community-dwelling patients with
dementia [36] and supports the use of this approach in
the outpatient setting. Moreover, the DICE method has
been suggested as the most promising nonpharmacologi-
cal approach to manage NPS in dementia [37]. Besides the
evidence on its effectiveness, demonstrating the cost-ef-
fectiveness of the DICE method is crucial before this
approach can be part of the standard care [18, 38].
The BEhavioral symptoms in Alzheimer’s disease
Towards early Identification and Treatment (BEAT-IT)
study is developed to increase our understanding of NPS
across the spectrum of AD. This project aims to (1)
investigate the etiology of the behavioral variant of
AD (bvAD) [39] as a model of the neurobiological
mechanisms of NPS in AD and (2) study the effec-
tiveness of the DICE method for the management of
NPS in patients with MCI and AD. This paper
describes the protocol of an intervention study that
focuses on the latter aim.
Objectives
The aim of this study is to use the DICE method to
structure and standardize the recognition of NPS in AD
in the memory clinic, implement current guidelines for
the treatment of NPS in MCI and AD, and to investigate
the effects of the treatment on QoL. Note that we will
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not evaluate the treatments itself (e.g., the efficacy of
psychosocial interventions or antidepressants) since
those are already evidence-based interventions recom-
mended by current guidelines, but rather examine the
benefits of structuring these interventions in the context
of the memory clinic. We will do this by investigating
the effectiveness and cost-effectiveness of the DICE
method in community-dwelling patients with AD or
MCI visiting the memory clinic and compare this group
to a control group who will receive care as usual (CAU).
We hypothesize that the structuring and standardization
of the care of NPS with the use of the DICE approach
will improve the QoL of both caregivers and patients at
the early stages of AD. In addition, implementing the
DICE method is expected to allow early recognition of
NPS and reduce NPS, caregiver burden, and psycho-
tropic drug use, and is aimed to be cost-effective. By
doing so, this study may contribute to the improvement
of early identification and management of NPS in AD in
memory clinics.
Methods
The Standard Protocol Items: Recommendations for In-
terventions Trials (SPIRIT) guidelines were followed for
this protocol [40].
Study design
This study is a prospective multicenter study with a
quasi-experimental design (see Fig. 1). In the first part of
the study, a control group will be recruited who will
receive CAU. After 1 year, we will enroll the second
wave of participants who will receive a structured and
standardized assessment and treatment of NPS based on
the principles of the DICE method. Hence, the enroll-
ment of the control group will be completed before the
start of the inclusion of the intervention group. This
design has the advantage that it reduces the risk of
contamination and crossover between the two groups.
Moreover, a crossover design is not possible given the pro-
gressive nature of AD. Furthermore, cluster randomization
of hospitals is not feasible because of the differences in
CAU between the sites. Since patients of both waves will be
enrolled in the same sites, we assume that the waves
will not show meaningful differences in demographic
and clinical characteristics. Also, no substantial changes
are expected in the upcoming years regarding current
CAU in the memory clinics based on the view of
collaborating experts and the organization of care in
the last years.
Subjects will be followed for 6 months while under-
going three assessments during this period. The primary
outcome will be the QoL of patients and their caregivers.
Secondary outcomes include changes in the prevalence
and severity of NPS, caregiver burden, caregivers’
confidence managing NPS, psychotropic medication
use, the experiences of patients and caregivers who
underwent the DICE method, and the cost-effectiveness
of the intervention.
Eligibility criteria
In order to be eligible to participate in this study,
patients must meet all of the following criteria (see
Table 1): (a) a clinical diagnosis of probable AD
(NIA-AA criteria by McKhann et al. [41]) or MCI due to
AD (NIA-AA criteria by Albert et al. [42]) with at
least intermediate probability of AD etiology based
on: patient history, neuropsychological assessment
[43], and neuroimaging (magnetic resonance imaging
(MRI) or positron-emission tomography (PET)). The
clinical diagnosis needs to be established within the
last 2 years so that patients with a diagnosis who visit
the memory clinic for clinical follow-up might also
participate; (b) presence of NPS established with the
Neuropsychiatric Inventory Questionnaire (NPI-Q, presence
Fig. 1 Design of the BEAT-IT study. Note that only the assessments are depicted since intervention visits will vary across subjects in the intervention
group due to the personalized approach
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of ≥ 1 symptoms) administered within the last month [44];
(c) a Mini-Mental State Examination (MMSE) score > 15 so
that patients are able to reflect on their QoL [45]; (d)
patients need to be community-dwelling; and (e)
availability of a reliable informant who is considered
to be the primary caregiver.
A potential subject who meets any of the following
criteria will be excluded from participation in this study:
(a) patients meet the (additional) criteria of any non-AD
neurodegenerative disease, except vascular co-pathology;
(b) legally incapable (as judged by the attending phys-
ician and therefore unable to give a written consent; (c)
evidence of current delirium or previous delirium in the
past 6 months; (d) primary (premorbid) psychiatric disor-
ders such as schizophrenia or bipolar disorder that could
better explain the manifestation of NPS, or current abuse
of alcohol or drugs; and (e) currently participating in a
clinical trial. Patients are allowed to be on medication
(e.g., acetylcholinesterase inhibitors or psychotropic
drugs) prior to inclusion since no differences between
the two waves are expected regarding the medication
use at baseline, and this will be carefully documented
in a case report form (CRF).
Recruitment
Patients will be recruited from six different memory
clinics in and around Rotterdam in the Netherlands
(Erasmus University Medical Center, Franciscus Gasthuis
& Vlietland, Het Van Weel-Bethesda Ziekenhuis,
Maasstad Hospital, and Spijkenisse Medical Center) to
facilitate patient enrollment and guarantee a good mixture
of patients from both academic and general hospitals.
After a diagnosis of MCI or AD dementia is estab-
lished at one of the memory clinics, study eligibility will
be evaluated based on the in- and exclusion criteria by the
local attending physician. Alternatively, patients already
diagnosed with MCI or AD dementia who visit the mem-
ory clinic for clinical follow-up will also be identified
based on these criteria.
Interventions
Control group
Participants in the control group will receive CAU at their
local hospital. We expect that the CAU will be quite
heterogeneous over sites and may consist of psychoeduca-
tion about dementia by a nurse or consultant specialized
in dementia, the prescription of psychotropic drugs, and/
or the referral to a psychiatric outpatient clinic for special-
ized treatment in patients with severe NPS [46]. Because
of these differences, we will carefully keep track of the
procedures undertaken by clinicians for patients in the
CAU group. Based on recommendations for assessing
usual care in clinical trial [47], we will develop a
study-specific CRF that will be filled out at the time of
enrolment and will be updated at each follow-up visit.
Intervention group
All participants in the second wave will be enrolled in
the intervention group. In this group, we will apply the
DICE method to structure and standardize the assess-
ment and management of NPS. Participants who with-
draw from study participation after being informed by
their physician and/or the researchers will receive CAU
at their hospital as described above. The DICE method
will take place at the Neurology Department of the
Erasmus MC and will be carried out by a psychiatrist
(MC) and neuropsychologists (EB, WSE, JMP) who are
all involved in the memory clinic of this department.
The steps of the DICE method are depicted in Fig. 2.
More detailed information on the development and
background of the DICE method can be found elsewhere
[10]. During the first visit, the patient and caregiver will
undergo a consultation by an experienced psychiatrist to
establish clinically relevant NPS (Describe). Factors
related to the patient, caregiver, and environment will be
examined following the DICE method [22, 48] and the
DICE manual [49]. For factors related to the patient, we
will record the chronic somatic conditions using the
Cumulative Illness Rating Scale for Geriatrics (CIRS-G)
[50] semi-structured interview, followed by a clinical
examination to explore the medication changes, pain,
sleep hygiene, and sensory changes. If necessary, a lab
evaluation will be conducted to screen for infections,
thyroid problems, and metabolic disorders. Other
patient-related factors including unmet needs, boredom,
and emotional well-being will be assessed using the
Checklist of Factors to Consider to Identify Potential
Causes of Behavioral Symptoms developed by Gitlin et
al. [48]. Caregiver-related factors will be screened by
using the Relationship Closeness Scale [51], Center for
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Diagnosis of MCI due to AD or AD
dementia based on patient history,
neuropsychological assessment,
and neuroimaging within the last
2 years
Meeting the additional criteria of a
non-AD neurodegenerative disease
(vascular co-pathology is permitted)
Presence of NPS; ≥ 1 symptoms
on NPI-Q
Legally incapable to give informed
consent
MMSE score > 15 Evidence of current delirium or
previous delirium
Patients need to be community-
dwelling
Primary (premorbid) psychiatric
disorders that could better explain
the manifestation of NPS
Availability of a reliable informant Participating in a clinical
(medication) trial
MCI mild cognitive impairment, AD Alzheimer’s disease, NPS neuropsychiatric
symptoms, NPI-Q Neuropsychiatric Inventory Questionnaire, MMSE Mini-Mental
State Examination
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Epidemiologic Studies Depression Scale [52], and the
CareQol-7D [53]. This will be extended by history taking
on family and cultural expectations, knowledge about
dementia, and the availability of support. Environmental
factors will be assessed to the patient and caregiver by
the Informal Assessment: Brief Questions to Guide
Describing Behavioral Symptoms [48]. A full and accu-
rate description of specific behavior will provide more
insight about the “who, when, where, and what” about
the situations in which the behavior is occurring, while
taking safety risks and the level of physical and social
stimulation into account (Investigate). Thereafter, a
multidisciplinary meeting will take place in which a
personalized treatment advice is formulated based on
the current guidelines on the diagnosis and assessment
of NPS in dementia (Create) [24–26]. During the second
visit, this treatment advice is discussed and adjusted to
the needs, values, and characteristics of the patient and
caregiver following a PCC approach. Given the large
heterogeneity in symptoms, interventions will vary for
each individual and can include psychoeducation, psycho-
social interventions, caregiver support, and/or pharmaco-
logical treatment based on the current (inter)national
guidelines [24–26, 54–56]. Notably, the interventions and
strategies that will be used to reduce NPS and enhance
the QoL are all evidence-based treatment strategies that
are or should be carried out in the current clinical prac-
tice. Finally, we will monitor treatment progression
1 month after the last visit by telephone (Evaluate).
Patients and their caregivers are then invited for an extra
visit if necessary. In such cases, alternative interventions
will be discussed if planned interventions were not imple-
mented or effective. Additional diagnostic procedures or
interventions will be monitored in the CRF.
Outcome measures
For the control group, measurements will take place at
baseline (T0), with follow-up testing at 3 months (T1)
and 6months (T2). For the intervention group, measure-
ments will take place at baseline (T0), directly after
treatment (T1), and follow-up at 6 months (T2). The
T1 measurements will be planned after finishing the
(psychosocial) intervention and/or when medication is
stabilized and thus may vary between subjects in the
intervention group. We will gather all relevant clinical and
intervention-related information which enables us to
study post hoc whether this variation in T1 assessments
may have resulted in bias. All measurements will take
place at the local hospitals or at the patients’ homes, see
Table 2 for an overview of all outcome measures.
Primary outcomes
The QoL of the patient will be measured by the Quality of
Life in Alzheimer’s Disease (QoL-AD) questionnaire [67].
This is one of the most widely used QoL questionnaires in
AD and has good psychometric properties [80]. Patients
are questioned via a 13-item interview format. The proxy
version of the QoL-AD is also used and filled out by the
caregiver since previous studies have shown that the
caregivers’ perspective on the patients’ QoL might be a
more valid indicator of treatment success [81].
The CarerQol-7D will be used to measure the care-re-
lated QoL in caregivers [53]. The instrument includes six
burden dimensions and a subjective valuation scale for
happiness.
Secondary outcomes
Changes in NPS will be assessed with the NPI-Q [44], a
general screening questionnaire including 12 distinct
NPS. For each item, caregivers have to indicate the pre-
sence, the severity, and the extent of emotional distress
that each symptom causes. Similar to Gitlin et al. [69],
we will add a frequency score and will ask caregivers
how confident they are in managing a certain symptom
on a 5-point Likert scale (0 = not confident to 4 = ex-
tremely confident).
Fig. 2 The DICE method with examples of questions and actions. Adapted from Kales et al. [10] and Gitlin et al. [48]
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A two-step approach will be used to further assess
NPS: if certain symptoms are present, as indicated by an
NPI-Q frequency score ≥ 1, specific questionnaires will
be used to assess these symptoms in more detail. All
instruments will be administered to the caregiver. To
measure the depressive symptoms, the Dutch version of
the Cornell Scale for Depression in Dementia (CSDD) will
be used [76]. The CSSD consists of 19 items covering
mood, behavioral changes, and circadian changes related
to depression and is validated in patients with dementia
[76]. Anxiety symptoms will be measured by the Rating
Anxiety in Dementia (RAID) scale, an 18-item inventory
that includes specific fears and somatic symptoms related
to anxiety [77]. Agitation, irritability, aggression, and
motor disturbances will be measured by the Dutch version
of the Cohen-Mansfield Agitation Inventory (CMAI-D)
[82]. Hallucinations will be assessed by the subscale B of
the Behavioral Pathology in Alzheimer’s Disease Rating
Scale (BEHAVE-AD) [78], and delusions will be assessed
by the subscale A of the BEHAVE-AD. Apathy is assessed
with the informant-reported Apathy Evaluation Scale
(AES-I) [75] and comprises of 18 items. Sleep distur-
bances will be measured by the 8-item Sleep Disorder
Inventory (SDI) [79], an expanded version of the sleep
disturbances item of the NPI. Similar to the NPI,
caregivers have to score each symptom of the SDI on
frequency, severity, and caregiver distress.
Caregiver burden will be measured with the per-
severance time, a one-item questionnaire that assesses
caregiver burden by asking the period of time (in months)
Table 2 Outcome measures
Outcome Measure Purpose Respondent Time of assessment
Demographic characteristics For example, age, education,
sex, ethnicity, relation to caregiver
Descriptive, covariate,
moderator
Patient and caregiver T0
Clinical characteristics For example, diagnosis, AD biomarkers,
disease duration
Descriptive, moderator Patient and caregiver T0*
Disease severity CDR [57] Descriptive, moderator Patient T0*, T2
Cognitive status MMSE [58] Descriptive, moderator Patient T0*, T2
Cognitive functioning Standardized cognitive test battery
[43]: RAVLT [59], VAT [60], DS [61],
VF [62], LDST [63], SCWT [64], TMT [65]
Descriptive, moderator Patient T0*
Functional abilities A-IADL-Q [66] Descriptive, moderator Caregiver T0, T2
Psychotropic medications Brown bag review [20] Descriptive, secondary
outcome
Caregiver T0, T1, T2
Comorbidities CIRS-G [50] Descriptive Patient T0, T2
Quality of life patient QoL-AD [67] Primary outcome Patient and caregiver T0, T1, T2
Quality of life caregiver CarerQol-7D [53] Primary outcome Caregiver T0, T1, T2
Caregiver burden Perseverance time [68] Secondary outcome Caregiver T0, T1, T2
Caregiver competence
managing NPS
Additional NPI-Q item [69] Secondary outcome Caregiver T0, T1, T2
Cost-effectiveness EQ-5D-5 L [70], ICECAP-O [71]
iMTA iVICQ [72], iMTA MCQ [73]
Secondary outcome Patient
Caregiver
T0, T1, T2
NPS prevalence, severity,
and distress
NPI-Q [44] Secondary outcome Caregiver T0*, T1, T2
If NPI-Q frequency score ≥ 1 on:
“Agitation,” “motor disturbances,”
“irritability,” “disinhibition”
Cohen-Mansfield Agitation
Inventory [74]
Secondary outcome Caregiver T0, T1, T2
“Apathy” Apathy Evaluation Scale-I [75] Secondary outcome Caregiver T0, T1, T2
“Depression,” “anxiety,” “elation” CSDD [76], RAID [77] Secondary outcome Caregiver T0, T1, T2
“Hallucinations,” “delusions” BEHAVE-AD subscales
psychosis, delusions [78]
Secondary outcome Caregiver T0, T1, T2
“Nighttime behaviors” Sleep Disorder Inventory [79] Secondary outcome Caregiver T0, T1, T2
AD Alzheimer’s disease, CDR Clinical Dementia Rating, RAVLT Rey Auditory Verbal Learning Test, VAT Visual Association Test, DS Digit Span, VF Verbal Fluency
(animals), LDST Letter Digit Substitution Test, SCWT Stroop Color Word Test, TMT Trail Making Test, MMSE Mini-Mental State Examination, A-IADL-Q Amsterdam
Instrumental Activity of Daily Living Questionnaire, CIRS-G Cumulative Illness Rating Scale for Geriatrics, QoL-AD Quality of Life in Alzheimer’s Disease, iMTA iVIQ
iMTA Valuation of Informal Care Questionnaire, iMTA MCQ iMTA Medical Costs Questionnaire, NPI-Q Neuropsychiatric Inventory Questionnaire, CSDD Cornell Scale
for Depression in Dementia, RAID Rating Anxiety In Dementia, BEHAVE-AD Behavioral Pathology in Alzheimer’s Disease Rating Scale
*Will be carried out during the diagnostic procedure at local hospitals
Eikelboom et al. Alzheimer's Research & Therapy           (2019) 11:48 Page 6 of 12
that the informal caregiver thinks he or she is able to
maintain the care if the current situation remains
stable [68]. This questionnaire is a good predictor for
institutionalization [83].
The Clinical Dementia Rating Scale (CDR), MMSE, and
a neuropsychological assessment will be administered
during the diagnostic procedure at the local memory
clinic prior to inclusion. The CDR includes six domains
covering cognitive function and IADL associated with
dementia [57]. Disease severity will be determined
based on clinical diagnosis and CDR global score with
MCI due to AD (CDR score 0.5), mild AD dementia
(CDR score 1), and moderate to severe AD dementia
(CDR score 2–3). Global cognitive function will be
measured with the MMSE [58]. The neuropsychological
assessment will be carried out according to the Dutch
Parelsnoer Institute for Neurodegenerative Diseases [40]
and covers the major cognitive domains including memory,
attention, processing speed, language, visuospatial abilities,
and executive functioning.
The Amsterdam Instrumental Activities of Daily Living
Questionnaire (A-IADL-Q) is a proxy measure to detect
problems in IADL in patients with dementia [66]. This
tool is a reliable and valid instrument to detect changes in
IADL over time.
Physical health and comorbidities of the patient will
be assessed using the CIRS-G [50]. The severity of 14
common medical problems in the geriatric population
(e.g., heart, liver, vascular diseases) will be judged by
one of the researchers during a short interview with
the patient and caregiver.
Psychotropic medication use will be documented in
the CRF. The total number of medications used will be
registered and classified according to the ATC coding:
antidepressants, antipsychotics, hypnotics and sedatives,
anxiolytics, and anti-dementia medications [20].
Cost-effectiveness
For the cost-effectiveness evaluation, patients will
complete the EQ-5D-5 L, the most commonly used
health-related QoL instrument [70], and the ICEpop
CAPability measure for Older people (ICECAP-O), a
5-item well-being scale [71], and caregivers will fill
out the CarerQol-7D. In addition, the Institute for
Medical Technology Assessment Valuation of In-
formal Care Questionnaire (iMTA iVICQ) [72] will
be used to assesses the amount, costs, and appraisal
of the care provided by the caregivers. The iMTA
Medical Consumption Questionnaire (iMTA MCQ)
consists of 31 questions regarding healthcare utilization
[73] and incorporates direct healthcare use of the
patient. Both the iMTA MCQ and the iMTA iVICQ
will be sent to the caregivers and can be completed
at home.
Qualitative endpoint data
A random selection of one out of four of the dyads in
the intervention group will be invited to participate in
the qualitative part of this study, accounting for the site
and disease stage. Semi-structured interviews will be
conducted in order to achieve more insight into the ex-
periences of participants who underwent the DICE
method and what they considered as helpful elements.
The interviews will be conducted face-to-face, will be
audio-taped, and will last approximately 60 min. Inter-
views will be performed until saturation is reached, i.e.,
until no new concepts and themes are obtained [84],
which we estimate to reach after we interviewed 15–20
patients with their caregivers [8, 85, 86]. Questions will
be asked in an open non-directive manner, focusing on
the subjects’ thoughts, feelings, and experiences. Topics
include the subjects’ experience of the intervention, and
which elements were considered to be effective and
which not, with the aim to examine the efficacy of and
experiences with the DICE method from the perspective
of patients and caregivers.
Sample size
In order to reach sufficient power to detect reliable and
clinically relevant changes, we performed a power calcu-
lation using G*Power. The power calculation is based on
the results of a recent meta-analysis by Kim and Park
[17], on the effectiveness of PCC in a mix of institution-
alized and community-dwelling patients, and the results
of a pilot study on the effectiveness of the DICE method
in community-dwelling patients and caregivers [36].
Both studies showed a moderate effect size for the
effects of PCC interventions on QoL in patients with
AD and their caregivers when compared to CAU. Since
there are limited validated sample size calculation
methods for the mixed model approach we aim to use
[87], our calculation is based on a repeated measures
ANOVA. Using G*Power, the required sample sizes were
N = 86 and N = 46 for between- and within-group
analyses, respectively, based on a power of 0.80 and an
alpha of 0.05. After enquiry, the 6 recruitment centers
suggested that at least 25 patients receive a MCI or AD
diagnosis annually at each site. Though there are a high
number of patients available at all 6 study sites, the
participation of eligible dyads is expected to be 150 since
not all patients will fulfill our criteria or will be willing
to participate (based on an estimated inclusion rate of
40% [88]). We will carefully keep track of the reasons
why eligible subjects refuse to participate. We will re-
cruit a total of 150 patients during the total inclusion
period of approximately 3 years (N = 75 in the control
group and N = 75 in the intervention group), which
exceeds the estimated needed sample size, even when
accounting for dropout/loss to follow-up.
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Statistical methods
T-tests or chi-square tests will be used to identify the
differences in baseline characteristics (e.g., age, education
level, disease severity) between the control group and the
intervention group. For the primary and secondary study
outcomes, we will use an intention-to-treat approach
including all subjects irrespective of the adherence to our
intervention [89]. Thereafter, we will perform per-protocol
analyses with only the subjects who completed the inter-
vention (underwent all DICE steps). We will correct for
multiple testing.
We will use the Little’s Missing Completely at Random
Test to examine whether the data are missing at random
or missing completely at random. The mixed model ana-
lyses will be able to handle the data when the missing
data is completely at random. Multiple imputation will
be used in cases when data is missing at random.
Linear mixed models will be used for the primary and
secondary outcomes for the T0, T1, and T2 time points.
These statistics are preferred when using longitudinal
data because of its advantage in handling missing data
and its capacity to deal with nested data and variance in
follow-up duration between and within the groups.
Changes in the trajectories of the primary and secondary
outcomes are compared between the two groups. Sub-
ject, hospital, and time are considered as random effects,
and baseline measure, group, and disease severity are
accounted as fixed effects.
We will perform a cost-utility analysis of the interven-
tion group versus the control group in accordance with
the Dutch guidelines for economic evaluations on the
basis of questionnaires [90].
Quality and length of life will be combined into
quality-adjusted life years (QALYs) using a Markov
model to extrapolate lifetime outcomes based on the
data from this study combined with literature data. The
EQ-5D-5 L, ICECAP-O, and CarerQol-7D data will be
transformed into QALYs for patients and caregivers
(well-being years for ICECAP-O), using published tariffs
obtained from general reference populations [90, 91].
With the simple Markov model, we will calculate the
incremental effectiveness of the DICE method versus the
control group in QALYs, incremental costs, and the
incremental cost-effectiveness ratios. We will also per-
form one-way, two-way, and probabilistic sensitivity
analyses to determine the effect of uncertainty in all
input parameters. Using a non-parametric bootstrapping
(randomly drawing 5000 observations with replacement
from the patient sample), the degree of uncertainty for
costs and health effects and the cost-utility ratio will be
depicted. In addition, an acceptability curve will be
drawn, which indicates the probability that the inter-
vention studied has lower incremental costs per QALY
gained than various thresholds.
A budget impact analysis will be performed that in-
cludes relevant features and tariffs of the Dutch health-
care system; anticipated uptake of the new intervention
as well as usual care will be considered. The budget
impact per year of implementing the new intervention
will be estimated. All elements of medical costs for the
intervention group and the control group will be consi-
dered and calculated.
Qualitative analyses
The audiotapes of all interviews will be transcribed ver-
batim. This data will be analyzed by two independent
researchers with ATLAS.ti 7 software according to the
thick analysis approach [92]. This approach endorses mul-
tiple triangulations, i.e., the use of multiple interpreters
and techniques to analyze the data, to enhance validity.
The coding and analyses will be an iterative process
simultaneously with the interviews, allowing adjustment
of questions and topics. We will make use of open
coding, thematic coding, and causal coding [93]. Open
coding is an explorative process in which all elements of
the data are coded. Thematic coding is a more deductive
technique that included the coding of themes and
categories that are proposed by the researchers prior to
the analysis or emerge from the material and are consi-
dered to be of importance by the researchers. Causal
coding will help us to get more insight into the working
elements of the DICE approach as proposed by the
participants. Characteristics of patients and their care-
givers (age, sex, relationship, disease severity) will be
used for descriptive purposes.
Discussion
The current paper describes the protocol of the BEAT-IT
study, a multicenter study designed to investigate the
effectiveness of a comprehensive assessment and per-
sonalized treatment of NPS in AD, following the DICE
method to improve the QoL in patients with MCI and
AD in the memory clinic. We hypothesize that early
recognition and tailored treatment of NPS will benefit
the QoL of patients and their caregivers; will reduce
NPS, caregiver burden, and psychotropic drug use; and
will lead to cost-effective care.
The novelty of this study lies in the inclusion of the
whole spectrum of NPS, the enrollment of both patients
with MCI and AD, and the evaluation of an approach
that integrates both nonpharmacological and pharma-
cological interventions in the memory clinic setting. Besides
standardized quantitative measures, a qualitative approach
will be used to examine its efficacy and feasibility from the
perspective of caregivers and patients. Also, important
additional information will be obtained from studying the
first wave of participants, enabling us to examine “natura-
listic” progression of NPS and its relationship with other
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clinical measures. Insight in the current CAU of NPS will
aid us in the formulation of recommendations to improve
the daily clinical practice regarding the care of NPS in AD.
After establishing the effectivity of the DICE method in the
memory clinic setting, a next step would be to examine the
implementation of this approach at other sites by taking
already suggested and unique local barriers into account.
At the time of writing, recruitment is ongoing and is
expected to be completed in December 2019 for the
control group. Hereafter, the intervention group will be
enrolled until the beginning of 2021, and follow-up
measures will be completed in autumn 2021. Results will
be available in late 2021.
There are a few possible threats to this study. Firstly, the
use of the NPI-Q to screen for eligible patients might
introduce an observer bias since this measure is not part
of the regular diagnostic workup at some sites. Con-
sequently, NPS may be detected more often, resulting in
care that may not fully reflect the current CAU, i.e.,
underestimating the expected underrecognition and
undertreatment of NPS in AD. Second, the current guide-
lines consider psychosocial interventions as the first-line
treatment but mainly suggest interventions that may be
more suitable for institutionalized patients with severe
dementia, e.g., reminiscence therapy, aromatherapy, or
“snoezelen” [24, 25]. Although various nonpharmacolo-
gical interventions have been shown to be effective in
community-dwelling patients [18], these strategies are
rarely mentioned in the guidelines and therefore not
integrated in clinical practice [94]. For our interventions,
we will select nonpharmacological strategies based on
prior studies (e.g., [48]) and our clinical expertise. Third,
our outcome measures are mainly based on self-reported
questionnaires that may not fully capture all effective
aspects of the intervention [95, 96]. Moreover, patients
with dementia may have difficulties completing the QoL
questionnaires (EQ-5D-5 L, ICECAP-O) due to cognitive
problems [97]. To circumvent some of these problems, we
will also use qualitative research methods which enables
us to better understand and measure the QoL of patients
and to give participants the opportunity to express their
experiences with the DICE method in an unrestricted
manner. Fourth, the substantial differences across sites in
CAU might be a challenge to this study, as patients
visiting certain sites may receive more and different treat-
ments compared to other centers. We will therefore aim
to record all valuable information through our CRF, which
enables us to perform post hoc sensitivity analyses, and
verify whether this heterogeneity might affect the results.
A final issue might be that patients are included based on
clinical diagnostic criteria, without the use of AD patho-
physiological biomarkers (e.g., abnormal levels of Aβ or
tau proteins in CSF or on PET). Despite the fact that an
MRI or (FDG-)PET scan of the brain is required, this may
lead to the inclusion of patients who do not have under-
lying AD pathology, especially in those with MCI. How-
ever, the applied diagnostic criteria resemble those that
are used in clinical practice where AD pathophysiological
biomarkers are not part of the standard diagnostic
workup. In addition, since this is a clinical study targeting
clinical symptoms rather than the underlying disease
process, we argue that the effects might be similar in
patients with other underlying etiologies. We will however
perform a sensitivity analysis in a subgroup of patients
with positive AD biomarkers in order to study whether
the effects are similar in this subgroup compared to the
whole study group.
To conclude, the BEAT-IT study as a whole will increase
our knowledge of the underlying neurobiology of NPS in
AD, which may enable us to identify potential targets for
therapeutic agents. The intervention study might provide
evidence on how to structure and standardize the care
of NPS in AD to improve the QoL of both caregivers
and patients. Moreover, the findings of the intervention
study will result in recommendations to improve the
early detection and treatment of NPS in AD in the
memory clinic.
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